US 2002/0165144 A1 · Human schizophrenia gene

Abstract

Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia.

Claims18

Dependent claims

A neuregulin 1 therapeutic agent selected from the group consisting of:

a neuregulin 1 gene or fragment or derivative thereof;
a polypeptide encoded by neuregulin 1 gene;
a neuregulin 1 receptor;
a neuregulin 1 binding agent;
a peptidomimetic;
a fusion protein;
a prodrug;
an antibody;
an agent that alters neuregulin 1 gene expression;
an agent that alters activity of a polypeptide encoded by neuregulin 1 gene;
an agent that alters posttranscriptional processing of a polypeptide encoded by neuregulin 1 gene;
an agent that alters interaction of a neuregulin 1 polypeptide with a neuregulin 1 binding agent;
an agent that its, alters activity of a neuregulin 1 binding agent;
an agent that alters transcription of splicing variants encoded by neuregulin 1 gene;
and a ribozyme.

12 more elements

Dependencies are inferred from the claim text.

Human schizophrenia gene

Life of this patent

Human schizophrenia gene

Life of this patent

Abstract

Claims18